Breaking News Instant updates and real-time market news.

MTSI

Macom

$30.36

1.79 (6.27%)

07:57
02/07/18
02/07
07:57
02/07/18
07:57

Macom downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Blayne Curtis downgraded Macom to Equal Weight and cut his price target for the shares to $26 from $40. The analyst calls the gross margin weakness in last night's quarter the "final straw." He is stepping to the sidelines pending "concrete proof" that the business is back on track.

  • 13

    Feb

  • 13

    Feb

MTSI Macom
$30.36

1.79 (6.27%)

01/05/18
DADA
01/05/18
UPGRADE
Target $43
DADA
Buy
Macom upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Mark Kelleher upgraded Macom to Buy from Neutral and raised his price target to $43 from $32, citing "rapid" adoption of 100GB technology and stabilization in the China business. Kelleher contends the company should be able to maintain mid-teens top and bottom line growth on 100GBP adoption in both the data center and service provider markets. The analyst adds that Macom affirmed its prior indication of early signs of China recovery at the DA Davidson optical conference in late December.
02/07/18
JPMS
02/07/18
DOWNGRADE
JPMS
Neutral
Macom downgraded to Neutral from Overweight at JPMorgan
02/07/18
DADA
02/07/18
NO CHANGE
Target $32
DADA
Buy
Macom price target lowered to $32 from $43 at DA Davidson
DA Davidson analyst Mark Kelleher lowered his price target on Macom to $32, citing a Q1 earnings miss and a compression in gross margins. Kelleher notes that the pressure came from "a market transition from LR4 transceivers to shorter-range CWDM" that "drove pricing of LR4 down significantly". The analyst keeps his Buy rating on Macom however, saying that while the impact of that transition will also be felt in Q2, longer term the ramp of higher-margin Laser/Photonic Integrated Circuit sales should pull gross margins back up towards the company's target of 60%.
02/07/18
JPMS
02/07/18
DOWNGRADE
Target $26
JPMS
Neutral
Macom downgraded to Neutral with reduced $26 target at JPMorgan
JPMorgan analyst Harlan Sur downgraded Macom to Neutral citing a "significantly reduced" forward earnings power outlook driven by push-outs from key cloud data center 100G customer engagements and significant margin pressures within the company's core telecom optical business. Following last night's weaker than expected earnings report the analyst cut his price target for the shares to $26 from $45.

TODAY'S FREE FLY STORIES

HPP

Hudson Pacific

$30.66

0.42 (1.39%)

05:41
02/23/18
02/23
05:41
02/23/18
05:41
Upgrade
Hudson Pacific rating change  »

Hudson Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

05:40
02/23/18
02/23
05:40
02/23/18
05:40
Downgrade
Rosneft rating change  »

Rosneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$37.41

-26.21 (-41.20%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Macquarie Infrastructure rating change  »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$41.84

-1.6 (-3.68%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Acacia Communications rating change  »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 13

    Mar

  • 29

    Mar

XPO

XPO Logistics

$93.56

-0.43 (-0.46%)

05:37
02/23/18
02/23
05:37
02/23/18
05:37
Recommendations
XPO Logistics analyst commentary  »

XPO free cash flow growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$39.85

0.34 (0.86%)

, BIVV

Bioverativ

$104.30

0.39 (0.38%)

05:35
02/23/18
02/23
05:35
02/23/18
05:35
Hot Stocks
Sanofi announces expiration of HSR waiting period for acquisition of Bioverativ »

Sanofi (SNY) announced…

SNY

Sanofi

$39.85

0.34 (0.86%)

BIVV

Bioverativ

$104.30

0.39 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

KNX

Knight-Swift

$47.83

-0.47 (-0.97%)

05:34
02/23/18
02/23
05:34
02/23/18
05:34
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGL

Sibanye Gold

$4.05

-0.38 (-8.58%)

05:26
02/23/18
02/23
05:26
02/23/18
05:26
Upgrade
Sibanye Gold rating change  »

Sibanye Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGIF

Ingenico Group

05:23
02/23/18
02/23
05:23
02/23/18
05:23
Downgrade
Ingenico Group rating change  »

Ingenico Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$30.53

-1.44 (-4.50%)

05:22
02/23/18
02/23
05:22
02/23/18
05:22
Hot Stocks
Momo acquires Tantan in cash, stock transaction »

Momo announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$55.43

-0.27 (-0.48%)

05:20
02/23/18
02/23
05:20
02/23/18
05:20
Recommendations
GoDaddy analyst commentary  »

GoDaddy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Mar

SRE

Sempra Energy

$106.64

1.21 (1.15%)

05:19
02/23/18
02/23
05:19
02/23/18
05:19
Hot Stocks
Sempra Energy raises annualized dividend by 9% to $3.58 per share »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

MB

Mindbody

$35.55

2.2 (6.60%)

05:18
02/23/18
02/23
05:18
02/23/18
05:18
Recommendations
Mindbody analyst commentary  »

Mindbody price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

FNGN

Financial Engines

$29.95

-0.45 (-1.48%)

05:17
02/23/18
02/23
05:17
02/23/18
05:17
Upgrade
Financial Engines rating change  »

Financial Engines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$35.82

0.49 (1.39%)

05:14
02/23/18
02/23
05:14
02/23/18
05:14
Initiation
Okta initiated  »

Okta initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 07

    Mar

COTV

Cotiviti Holdings

$34.21

-0.32 (-0.93%)

05:11
02/23/18
02/23
05:11
02/23/18
05:11
Downgrade
Cotiviti Holdings rating change  »

Cotiviti downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARD

Ardagh Group

$19.01

0.8 (4.39%)

05:09
02/23/18
02/23
05:09
02/23/18
05:09
Recommendations
Ardagh Group analyst commentary  »

Ardagh should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$26.48

-0.29 (-1.08%)

05:03
02/23/18
02/23
05:03
02/23/18
05:03
Initiation
Boston Scientific initiated  »

Boston Scientific assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

SGMO

Sangamo

$25.40

3.2 (14.41%)

, GILD

Gilead

$79.40

-1.29 (-1.60%)

05:00
02/23/18
02/23
05:00
02/23/18
05:00
Recommendations
Sangamo, Gilead analyst commentary  »

Sangamo price target…

SGMO

Sangamo

$25.40

3.2 (14.41%)

GILD

Gilead

$79.40

-1.29 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$101.51

0.42 (0.42%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Eastman Chemical management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

Week of 2/23 Baker-Hughes…

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

San Francisco Federal…

UMICY

Umicore

$14.37

-0.185 (-1.27%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Umicore management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

RYTM

Rhythm Pharmaceuticals

$26.06

0.01 (0.04%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Rhythm Pharmaceuticals management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Deutsche Bank to hold a conference »

Indonesia Corporate Days…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.